Chemotherapy

Cytogenetic findings in patients diagnosed with breast cancer having undergone adjuvant chemotherapy regimens

P. A. Koşar, Koçer, M., Çelik, D. A., Ozcelik, N., Koşar, P. A., Koçer, M., Çelik, D. A., Ozcelik, N., Koşar, P. A., Koçer, M., Çelik, D. A., and Ozcelik, N., “Cytogenetic findings in patients diagnosed with breast cancer having undergone adjuvant chemotherapy regimens”, vol. 15, p. -, 2016.

The aim of the present study was to investigate DNA damage in peripheral blood lymphocytes of breast cancer (BC) patients before and after administration of chemotherapy. We analyzed the frequency of sister chromatid exchange (SCE), occurrence of micronuclei (MN), and lymphocyte proliferation rate index (PRI) as cytogenetic markers in 28 female BC patients before and after chemotherapy, and in 20 age-matched healthy female volunteers. Prior to treatment, BC patients showed significantly increased background levels of SCE and MN, and lowered PRIs compared to healthy women.

Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma

R. Wang, Jing, G., Lv, J., Song, H., Li, C., Wang, X., Xia, W., Wu, Y., Ren, G., and Guo, W., “Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma”, vol. 14, pp. 11944-11954, 2015.

Two major subtypes of melanoma include cutaneous melanoma and mucosal melanoma. The latter type is rare and usually occurs in the head and neck region. High-dose interferon-α-2b (IFN-α-2b) has proven effective in the treatment of cutaneous melanoma. Recently, a regimen of temozolomide plus cisplatin was reported more likely to improve relapse-free survival and overall survival than high-dose IFN-α-2b for mucosal melanoma. We conducted this study to analyze the therapeutic effect of high-dose IFN-α-2b for patients with oral mucosal melanoma who had received prior chemotherapy.

Predictive potential role of glutathione S-transferases polymorphisms in response to chemotherapy and breast cancer prognosis

P. Yuan, Yuan, L., Xu, B. L., Wang, C. Z., Yang, H. Z., and Li, Y., “Predictive potential role of glutathione S-transferases polymorphisms in response to chemotherapy and breast cancer prognosis”, vol. 14, pp. 16675-16681, 2015.

The aim of this study was to evaluate the role of GSTM1 null/present, GSTT1 null/present, and GSTP1 polymorphisms in the clinical response to chemotherapy and treatment outcome of breast cancer. The GSTM1, GSTT1, and GSTP1 IIe105Val polymorphism genotypes were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism.

Expression of TRAIL and its receptor DR5 and their significance in acute leukemia cells

S. M. Chen, Sun, H., Liu, Y. F., Ma, J., Zhang, Q. T., Zhu, J., and Li, T., “Expression of TRAIL and its receptor DR5 and their significance in acute leukemia cells”, vol. 14, pp. 18562-18568, 2015.

We investigated the roles of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptor death receptor 5 (DR5) in the onset of acute leukemia and changes in their expression during chemotherapy. Bone marrow samples from 16 patients newly diagnosed with acute leukemia were collected before chemotherapy. Bone marrow samples from patients with non-hematologic malignancies served as the control group. Peripheral blood samples of patients with acute leukemia were also collected before chemotherapy and at 1 and 3 days after chemotherapy.

Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer

J. Wang, Wang, T., Yin, G. - Y., Yang, L., Wang, Z. - G., and Bu, X. - B., “Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer”, vol. 14, pp. 11126-11132, 2015.

The aim of this study was to evaluate the role of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymor­phisms in the clinical response to chemotherapy and treatment outcome of patients with breast cancer. A total of 262 subjects were randomly selected from among patients with a histologically confirmed breast cancer. The genotypes of GSTM1, GSTT1, and GSTP1 IIe105Val poly­morphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis.

Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma

Q. Zhang, Lv, L. Y., Li, B. J., Zhang, J., and Wei, F., “Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma”, vol. 14, pp. 11235-11241, 2015.

We assessed the role of single nucleotide polymorphisms (SNPs) in ERCC1 and ERCC2 genes in the clinical outcomes for osteosarcoma patients receiving cisplatin-based treatment. A perspective study was conducted on 260 patients with osteosarcoma during 2010 and 2011. A polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was used to assess the ERCC1 rs11615 and rs3212986, and the ERCC2 rs1799793 and rs13181 gene polymorphisms.

Subscribe to Chemotherapy